Pricing
  1. JP-listed companies
  3. Financials
  4. Operating margin (%)

【JP:4597】

Market cap
¥7B
P/E ratio
Develops and commercializes innovative cancer medicines across Asian markets including Japan, China, and South Korea, focusing on treatments and supportive care.
SummaryFinancialsDividendsHistoryOwnershipWorkforce
Period EndOperating margin (%) YoY (%)
Dec 31, 2025-203-67.12%
Dec 31, 2024-617.4+234.45%
Dec 31, 2023-184.6-18.39%
Dec 31, 2022-226.2-47.73%
Dec 31, 2021-432.7-52.27%
Dec 31, 2020-906.6+574.04%
Dec 31, 2019-134.5-82.73%
Dec 31, 2018-778.6+110.28%
Dec 31, 2017-370.3+87.33%
Dec 31, 2016-197.7-65.28%
Dec 31, 2015-569.2

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)